Similar articles

• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Escudier B, et al. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7. Lancet. 2007. PMID: 18156031 Clinical Trial.
• Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

  Frampton JE, Keating GM. Frampton JE, et al. BioDrugs. 2008;22(2):113-20. doi: 10.2165/00063030-200822020-00004. BioDrugs. 2008. PMID: 18345708 Review.
• Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

  Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Escudier B, et al. J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368553 Clinical Trial.
• Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France.: J Clin Oncol. 2014 Mar 10;32(8):752-9; doi: 10.1200/JCO.2013.50.5305. [Epub 2013 Dec 2].

  Trump D. Trump D. Urol Oncol. 2016 May;34(5):250-1. doi: 10.1016/j.urolonc.2015.03.014. Epub 2015 Apr 30. Urol Oncol. 2016. PMID: 25937425
• Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.

  Melichar B, Procházková-Študentová H, Vitásková D. Melichar B, et al. Expert Rev Anticancer Ther. 2012 Oct;12(10):1253-61. doi: 10.1586/era.12.103. Epub 2012 Nov 8. Expert Rev Anticancer Ther. 2012. PMID: 23136836 Review.